Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 12/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 10/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6084492 | 1.00 | CA2 (0.59) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL1383106 | 1.00 | CA2 (0.59) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL3487482 | 0.98 | CA2 (0.57) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL6085529 | 0.98 | CA2 (0.57) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Bicarbonate SCHEMBL6086499 | 0.92 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7393368 | 0.89 | CA2 (0.49) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Maleic Acid SCHEMBL6086191 | 0.87 | CA2 (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| Fumaric Acid SCHEMBL6086194 | 0.87 | CA2 (0.51) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL407503 | 0.86 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4936349 | 0.83 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4790910-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| US-20060229339-A1 | Novel use of substituted aminomethyl chromans | MERCK PATENTGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | claimed |
| EP-1425008-B1 | USE OF SUBSTITUTED AMINOMETHYL CHROMANS IN THE TREATMENT OF SIDE EFFECTS OF NEUROLEPTICS | MERCK PATENT GMBH (DE) | 2006-10-04 | — | — | EP | claimed |
| US-7045629-B2 | Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane | MERCK PATENT GMBH (DE) | 2006-05-16 | — | — | US | claimed |
| CN-1714089-A | Novel use of substituted aminomethyl chromans | MERCK PATENT GMBH (DE) | 2005-12-28 | — | — | CN | claimed |
| EP-1383763-B1 | METHOD FOR PRODUCING 2-(-5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL)-CHROMANE | MERCK PATENT GMBH (DE) | 2005-10-12 | — | — | EP | claimed |
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | KANEKA CORPORATION (JP) | 2005-01-20 | — | — | US | claimed |
| CN-1564818-A | Stereoselective synthesis method of 2-hydroxymethyl-chroman | WYETH CORP (US) | 2005-01-12 | — | — | CN | claimed |
| CN-1561337-A | Stereospecific process for the synthesis of 2-yl chroman derivatives | WYETH CORP (US) | 2005-01-05 | — | — | CN | claimed |
| CN-1555259-A | use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders | Ĭ��ר���ɷ�����˾ | 2004-12-15 | — | — | CN | claimed |
| EP-0540914-B1 | 2-Aminomethylchromans as active ingredients in medicaments for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1999-06-02 | — | — | EP | claimed |
| CN-1143079-A | Benzoisothiazolyl-substituted aminomethyl chromans | BAYER AG (DE) | 1997-02-19 | — | — | CN | claimed |
| US-5585392-A | TREATING OR PREVENTING STROKES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-12-17 | — | — | US | claimed |
| US-5506246-A | Method for treating depression using substituted aminomethyltetralins and their heterocyclic analogues | BAYER AKTIENGESELLSCHAFT (DE) | 1996-04-09 | — | — | US | claimed |
| US-5364857-A | Combination having a neuroprotective effect | TROPONWERKE GMBH & CO KG (DE) | 1994-11-15 | — | — | US | claimed |
| US-5318988-A | Treating psychoses | BAYER AKTIENGESELLSCHAFT (DE) | 1994-06-07 | — | — | US | claimed |
| CN-1024667-C | process for preparing substituted aminomethyl tetralins and substituted aminomethyl hydrogenated benzopyrans and their salts | BAYER AG (DE) | 1994-05-25 | — | — | CN | claimed |
| US-5300523-A | Binding serotonin receptors, treating nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1994-04-05 | — | — | US | claimed |
| EP-0540914-A1 | 2-Aminomethylchromans as active ingredients in medicaments for the treatment of diseases of the central nervous system | BAYER AG (DE) | 1993-05-12 | — | — | EP | claimed |
| US-5137901-A | For binding 5-HT 1 receptors; treating central nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229339-A1 | Novel use of substituted aminomethyl chromans | CHRM1, HTR1D, COMT | CA2 4051/4885HTR1A 6/4885SIGMAR1 231/4885 |
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | CYP8B1, CYP3A43, HPD | CA2 825/4885HTR1A 739/4885SIGMAR1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.